The overlooked primary: bladder cancer metastases on dry bone. A study of the 20th century CAL Milano Cemetery Skeletal Collection

2019 ◽  
Vol 24 ◽  
pp. 130-140 ◽  
Author(s):  
Lucie Biehler-Gomez ◽  
Gaia Giordano ◽  
Cristina Cattaneo
Keyword(s):  
Bladder Cancer ◽  
20Th Century ◽  
Cancer Metastases ◽  
Primary Bladder ◽  
Dry Bone ◽  
Primary Bladder Cancer

scholarly journals Gender Differences in Pathologic Outcomes At Primary Bladder Cancer Detection

2015 ◽  
Author(s):  
Rahmi Gökhan Ekin ◽  
Zübeyde Yıldırım Ekin ◽  
Gökhan Koç ◽  
Ayşe Gülden Diniz Ünlü ◽  
Yusuf Özlem İlbey ◽  
...  
Keyword(s):  
Gender Differences ◽  
Bladder Cancer ◽  
Cancer Detection ◽  
Primary Bladder ◽  
Primary Bladder Cancer

scholarly journals PELVIC LYMPH NODE INVOLVEMENT IN PRIMARY BLADDER CANCER

1995 ◽  
Vol 86 (4) ◽  
pp. 919-926 ◽  
Author(s):  
Osamu Kuriki ◽  
Yoshinari Ono ◽  
Norio Katoh ◽  
Masafumi Sahashi ◽  
Tsuneo Kinukawa ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Lymph Node Involvement ◽  
Pelvic Lymph Node ◽  
Node Involvement ◽  
Primary Bladder ◽  
Pelvic Lymph Node Involvement ◽  
Primary Bladder Cancer

scholarly journals Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer

2019 ◽  
Vol 202 (12) ◽  
pp. 3458-3467 ◽  
Author(s):  
Vid Leko ◽  
Lucas A. McDuffie ◽  
Zhili Zheng ◽  
Jared J. Gartner ◽  
Todd D. Prickett ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Infiltrating Lymphocytes ◽  
Primary Bladder ◽  
Infiltrating Lymphocytes ◽  
Primary Bladder Cancer

scholarly journals Preoperative Glasgow prognostic score as a predictor of primary bladder cancer recurrence

2016 ◽  
Vol 5 (1) ◽  
pp. 201-206 ◽  
Author(s):  
OZGUR HAKI YUKSEL ◽  
SERKAN AKAN ◽  
AHMET URKMEZ ◽  
CAGLAR YILDIRIM ◽  
AYTAC SAHIN ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Cancer Recurrence ◽  
Primary Bladder ◽  
Bladder Cancer Recurrence ◽  
Primary Bladder Cancer

scholarly journals Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up

2020 ◽  
Author(s):  
Kim Tae-Min ◽  
Jinseon Yoo ◽  
Hyong Woo Moon ◽  
Kyung jae Hur ◽  
Jin Bong Choi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Somatic Mutations ◽  
Circulating Tumor Cell ◽  
Cancer Tissue ◽  
Matched Pairs ◽  
Primary Bladder ◽  
Primary Bladder Cancer

Abstract Background: While circulating tumor cells may serve as minimally invasive cancer markers for bladder cancers, the relationship between primary bladder cancers and circulating tumor cells in terms of somatic mutations is largely unknown. Genome sequencing of bladder tumor and circulating tumor cells is highlighted to identify the somatic mutations of primary bladder cancer.Methods: Bladder cancer tissue was collected by transurethral resection of the bladder and preserved by snap-freezing. Circulating tumor cells were Isolated from the blood obtained before treatment. We performed whole exome sequencing of 20 matched pairs of primary bladder cancers and circulating tumor cells to identify and compare somatic mutations of these two different genomic resources.Results: We observed that mutation abundances of primary bladder cancers and circulating tumor cells were highly variable. The mutation abundance was not significantly correlated between matched pairs. Of note, the mutation concordance between two resources was only 3 – 24% across 20 pairs examined, suggesting that the circulating tumor cell genomes of bladder cancer patients might be genetically distinct from primary bladder cancers. A relative enrichment of mutations belonging to APOBEC-related signature and a depletion of C-to-G transversions were observed for primary- and circulating tumor cells specific mutations, respectively, suggesting that distinct mutation forces might have been operative in respective lesions during carcinogenesis. Conclusions: The observed discrepancy of mutation abundance and low concordance level of mutations between genomes of primary bladder cancers and circulating tumor cells should be taken into account when evaluating clinical utility of circulating tumor cells for treatments and follow-up of bladder cancers.Trial registration: Patients were selected and registered retrospectively, and medical records were evaluated.

scholarly journals Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Tae-Min Kim ◽  
Jin-seon Yoo ◽  
Hyong Woo Moon ◽  
Kyung Jae Hur ◽  
Jin Bong Choi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Somatic Mutations ◽  
Circulating Tumor Cell ◽  
Cancer Tissue ◽  
Matched Pairs ◽  
Primary Bladder ◽  
Primary Bladder Cancer

Abstract Background While circulating tumor cells may serve as minimally invasive cancer markers for bladder cancers, the relationship between primary bladder cancers and circulating tumor cells in terms of somatic mutations is largely unknown. Genome sequencing of bladder tumor and circulating tumor cells is highlighted to identify the somatic mutations of primary bladder cancer. Methods Bladder cancer tissue was collected by transurethral resection of the bladder and preserved by snap-freezing. Circulating tumor cells were Isolated from the blood obtained before treatment. We performed whole exome sequencing of 20 matched pairs of primary bladder cancers and circulating tumor cells to identify and compare somatic mutations of these two different genomic resources. Results We observed that mutation abundances of primary bladder cancers and circulating tumor cells were highly variable. The mutation abundance was not significantly correlated between matched pairs. Of note, the mutation concordance between two resources was only 3–24% across 20 pairs examined, suggesting that the circulating tumor cell genomes of bladder cancer patients might be genetically distinct from primary bladder cancers. A relative enrichment of mutations belonging to APOBEC-related signature and a depletion of C-to-G transversions were observed for primary- and circulating tumor cells specific mutations, respectively, suggesting that distinct mutation forces might have been operative in respective lesions during carcinogenesis. Conclusions The observed discrepancy of mutation abundance and low concordance level of mutations between genomes of primary bladder cancers and circulating tumor cells should be taken into account when evaluating clinical utility of circulating tumor cells for treatments and follow-up of bladder cancers. Trial registration Patients were selected and registered retrospectively, and medical records were evaluated.

Sign in / Sign up

Export Citation Format

Share Document